Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.

@article{Hiligsmann2010CosteffectivenessOS,
  title={Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.},
  author={Micka{\"e}l Hiligsmann and Olivier Bruy{\`e}re and J -Y Reginster},
  journal={Bone},
  year={2010},
  volume={46 2},
  pages={440-6}
}
OBJECTIVE To estimate the cost-effectiveness of strontium ranelate in the treatment of postmenopausal osteoporotic women aged over 75 years. MATERIALS AND METHODS A validated Markov microsimulation model with a Belgian payer's perspective estimated the cost per quality-adjusted life-year (QALY) of a 3-year strontium ranelate treatment compared with no treatment and with the bisphosphonate risedronate. Data on the effect of both treatments on fracture risk were taken from the Cochrane Database… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Strontium Ranelate

View 7 Excerpts
Highly Influenced

The application of health technology assessment in osteoporosis.

Best practice & research. Clinical endocrinology & metabolism • 2014

Health Technology Assessment in Osteoporosis

Calcified Tissue International • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…